UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,119 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 8.2% during the third quarter, Holdings Channel.com reports. The fund owned 191,065 shares of the company’s stock after selling 17,119 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Apellis Pharmaceuticals were worth $5,510,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Wolverine Asset Management LLC bought a new stake in Apellis Pharmaceuticals in the 3rd quarter worth $27,000. Capital Performance Advisors LLP bought a new stake in Apellis Pharmaceuticals in the 3rd quarter worth $56,000. KBC Group NV grew its holdings in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after acquiring an additional 679 shares during the last quarter. nVerses Capital LLC grew its holdings in Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after acquiring an additional 2,100 shares during the last quarter. Finally, CWM LLC grew its holdings in Apellis Pharmaceuticals by 299.9% in the 2nd quarter. CWM LLC now owns 4,151 shares of the company’s stock worth $159,000 after acquiring an additional 3,113 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

APLS has been the topic of a number of recent analyst reports. Bank of America cut their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating on the stock. Wells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Needham & Company LLC cut their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Finally, Oppenheimer cut their target price on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Stock Performance

Shares of NASDAQ APLS opened at $34.64 on Wednesday. The firm has a market capitalization of $4.31 billion, a price-to-earnings ratio of -17.06 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80. The firm has a 50 day moving average of $29.34 and a 200 day moving average of $34.88. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.17) earnings per share. On average, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Insider Transactions at Apellis Pharmaceuticals

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The trade was a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.80% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).